EPAS1 and nonpapillary renal cell carcinoma: Targeting HIF2α is of particular interest in cancer therapy since HIF2α is the transcription factor of numerous genes that have been involved not only in the development of CCRCC growth [20,21,25,26] but also in the development of other type of tumors [27,28].